CN Patent

CN104496952B — 一种达格列净的合成方法

Assigned to Hybio Pharmaceutical Co Ltd · Expires 2017-04-19 · 9y expired

What this patent protects

本发明涉及一种达格列净的合成方法，采用卤代苯衍生物和2,3,4,6,‑四乙酰氧基‑α‑D‑吡喃葡萄糖溴化物为原料，省去了原方法中的还原反应和乙酰基化反应，缩短了反应工艺步骤，提高了总收率。将苯锂试剂制备成反应较温和的铜锂试剂或格氏试剂中间体，减少了副产物的产生，反应温度控制在‑10℃以下即可。

USPTO Abstract

本发明涉及一种达格列净的合成方法，采用卤代苯衍生物和2,3,4,6,‑四乙酰氧基‑α‑D‑吡喃葡萄糖溴化物为原料，省去了原方法中的还原反应和乙酰基化反应，缩短了反应工艺步骤，提高了总收率。将苯锂试剂制备成反应较温和的铜锂试剂或格氏试剂中间体，减少了副产物的产生，反应温度控制在‑10℃以下即可。

Drugs covered by this patent

Patent Metadata

Patent number
CN104496952B
Jurisdiction
CN
Classification
—
Expires
2017-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Hybio Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.